Published date: Oct 25 2020

Journal Title: Journal of Ophthalmic and Vision Research

Issue title: October–December 2020, Volume 15, Issue 4

Pages: 459–469

DOI: 10.18502/jovr.v15i4.7786

Asima BajwaMassachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts

Arash MalekiMassachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts

Abhishek R PayalMassachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts; University of Pennsylvania, Scheie Eye Institute, Philadelphia, Pennsylvania

Adriana FandiñoMassachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts

María Inés Menéndez PadrónMassachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts

Marisa WalshMassachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts

Charles Stephen Fostersfoster@mersi.comMassachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Harvard Medical School, Boston, Massachusetts; Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts

Purpose: To determine the efficacy and safety of infliximab therapy in patients with HLA B-27-associated ocular inflammation resistant or intolerant to conventional immunomodulatory therapy.

Methods: This was a retrospective observational case series. All cases were uveitic patients with positive HLA-B27, confirmed through HLA testing, resistant or intolerant to conventional immunomodulatory therapy. The primary outcome of the study was to identify the efficacy of infliximab determined by the control of inflammation, duration of remission, and the ability to reduce conventional immunomodulatory therapy. The secondary outcome was an improvement of two or more lines of best-corrected visual acuity (BCVA) on the Snellen visual acuity chart.

Results: Twenty-four patients (38 eyes) were included in the study. All patients were followed for 24 months. Twenty-one (87.5%) patients completed 24 months of follow-up. Sixteen (66.7%) patients had active uveitis at the beginning of therapy. One patient out of these active patients had active inflammation at the end of follow-up period. Thirteen (87.5%) out of sixteen active patients were in steroid-free remission. The mean duration of treatment to induce remission was 16.5 months (range 6–24 months). Corticosteroid was stopped in 19 (90.5%) patients by the end of the study. At the end of the study, in patients who achieved remission, 14 (58.3%) patients were in remission on infliximab therapy and 6 (25%) patients were in remission off infliximab therapy. Of the 38 eyes, 8 (21.05%) showed improvement in BCVA (three eyes had successful cataract extraction with intraocular lens implantation during infliximab therapy with no subsequent inflammation), while 26 eyes (68.4%) had stable BCVA over the 24-month study period. The side effects included allergic reaction, fatigue, cellulitis, headache, restlessness, elevation of liver enzymes, and anemia. Two patients (n = 24, 8.3%) experienced severe adverse effects and the treatment was stopped prematurely in these two patients.

Conclusion: Infliximab might induce and maintain the steroid-free remission in HLAB27- associated ocular inflammation in patients resistant or intolerant to conventional immunomodulatory therapy.

1. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol 2005;50:364–388.

2. Ramsay A, Lightman S. Hypopyon uveitis. Surv Ophthalmol 2001;46:1–18.

3. Anshu A, Chee SP. Posterior scleritis and its association with HLA B27 haplotype. Ophthalmologica 2007;221:275– 278.

4. Loh AR, Acharya NR. Incidence rates and risk factors for ocular complications and vision loss in HLA-B27- associated uveitis. Am J Ophthalmol 2010;150:534– 542.e2.

5. De Vos AF, Klaren VN, Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994;35:3873–3883.

6. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato- Cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 2005;19:841– 845.

7. Lopez-Gonzalez R, Loza E, Jover JA, Benitez Del Castillo JM, Mendez R, Hernandez-Garcia C, et al. Treatment of refractory posterior uveitis with infliximab: a 7-year followup study. Scand J Rheumatol 2009;38:58–62.

8. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449–1453.

9. El-Shabrawi Y, Mangge H, Hermann J. Anti-tumour necrosis factor alpha treatment in chronic recurrent inflammation of the anterior segment of the eye in patients resistant to standard immunomodulatory treatment. Ann Rheum Dis 2003;62:1243–1244.

10. Suhler EB, Smith JR, Giles TR, Lauer AK, Wertheim MS, Kurz DE, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009;127:819–822.

11. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007;125:895– 900.

12. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factoralpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002;109:2342–2346.

13. Gueudry J, Thorne JE, Bansie R, Braun J, van Hagen PM, Bodaghi B. Biologic therapy for HLA-B27-associated ocular disorders. Ocul Immunol Inflamm 2017;25:169–178.

14. Kim M, Won JY, Choi SY, Ju JH, Park YH. Anti-TNFα treatment for HLA-B27-positive ankylosing spondylitisrelated uveitis. Am J Ophthalmol 2016;170:32–40.

15. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 2005;140:509–516.

16. Harper SL, Chorich LJ, Foster CS. Diagnosis of uveitis. In: Foster CS, Vitale AT, editors. Diagnosis and treatment of uveitis. Philadelphia, PA: WB Saunders Co; 2002:79–103.

17. Sen HN, Sangava AA, Goldstein DA, et al. A standardized grading system for scleritis. Ophthalmology 2011;118:768– 771.

18. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973;1:904–907.

19. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973;288:704–706.

20. Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Estevez E. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 2004;20:155–157.

21. De Vos AF, Klaren VN, Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994;35:3873–3883.

22. Koizumi K, Poulaki V, Doehmen S, Welsandt G, Radetzky S, Lappas A, et al. Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci 2003;44:2184–2191.

23. Sartani G, Silver PB, Rizzo LV, Chan CC, Wiggert B, Mastorakos G, et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci 1996;37:2211–2218.

24. Mo JS, Matsukawa A, Ohkawara S, Yoshinaga M. Involvement of TNF alpha, IL-1 beta and IL-1 receptor antagonist in LPS-induced rabbit uveitis. Exp Eye Res 1998;66:547–557.

25. El-Shabrawi Y, Wegscheider BJ, Weger M, Renner W, Posch U, Ulrich S, et al. Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: association with susceptibility and clinical manifestations. Ophthalmology 2006;113:695–700.

26. Pasadhika S, Suhler E, Emmett Jr C. Use of biologic agents in the treatment of uveitis. Rev Ophthalmol Retin Insid 2010. Available from: http://www.reviewofophthalmology. com/content/d/retinal_insider/i/1208/c/22770/ (accessed Nov 5, 2013).

27. Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005;43:7– 11.

28. Matsuda J, Kaburaki T, Kobayashi S, Numaga J. Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis. Jpn J Ophthalmol 2013;57:104–107.

29. Foeldvari I, Nielsen S, Kummwele-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second line agents: results of a multinational survey. J rheumatol 2007;34:1146–1150.

30. Nguyen QD, Merrill PT, Jafe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016;388:1183–1192.

31. Suhler EB, Adan A, Brezin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology 2018;125:1075–1087.

32. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903–912.

33. Kim M, Won JY, Choi SY, Ju JH, Park YH. Anti-TNFα treatment for HLA-B27-postive Ankylosing spondylitisrelated uveitis. Am J Ophthalmol 2016;170:32–40.

34. El-shabrawi W, Hermann J. Case series of selective antitumor necrosis factor alpha therapy using infliximab in patients with nonresponsive chronic HLA-B27- associated anterior uevitis: commnet on the articles by Brandt et al. Arthritis Rheum 2002;46:2821–2822.

35. Paccou J, Baclé-Boutry M-A, Solau-Gervais E, Bele- Philippe P, Flipo RM. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J Rheumatol 2012;39:1418–1423.

36. Richards JC, Tay-Kearney M-L, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Experiment Ophthalmol 2005;33:461–468.

37. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006;113:308–314.

38. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006;113:8604.e2.

39. Petropoulos IK, Vaudaux JD, Guex-Crosier Y. Anti-TNFalpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd 2008;225:457–461.